Skip to main content

H.R. 7515

Referred to Committee

Infectious Disease Therapies Research and Innovation Act of 2022

Introduced 4/14/2022•117th Congress•House

Latest Action

Referred to the House Committee on Ways and Means.

4/14/2022 • House

Summary

Infectious Disease Therapies Research and Innovation Act of 2022

This bill exempts from the definition of passive activity, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.

The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.

Introduced in House • 4/14/2022

Enter your district to see how this bill affects your community
-

Topics & Subjects

Policy Area: Taxation

Congressional Votes (0)

No recorded votes yet

Roll call votes will appear here as the bill moves through Congress

Related Federal Spending

Sponsor & Cosponsors (3)

Party Breakdown

0
Democrats
3
Republicans
0
Independents

Sponsor

R[
Rep. Kelly, Mike [R-PA-16]

Republican • PA-16

Sponsored 4/14/2022

Cosponsors (2)

R[
Rep. Buchanan, Vern [R-FL-16]

R-FL-16

Joined 4/14/2022

R[
Rep. Wenstrup, Brad R. [R-OH-2]

R-OH-2

Joined 4/14/2022

Bill Journey

Originated in the House

Introduced

April 14, 2022

Referred to the House Committee on Ways and Means.

Committee Review

Floor Debate

Passed Chamber

Other Chamber

President

Enacted into Law

Text Versions (1)

Introduced in House4/14/2022

Details

Bill TypeHR
Current StatusReferred to Committee
Cosponsors2